Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Pacira BioSciences Analyst Ratings and Price Targets | NASDAQ:PCRX | Benzinga
Pacira BioSciences Inc has a consensus price target of $36.77 based on the ratings of 13 analysts. The high is $65 issued by HC Wainwright & Co. on April 8, 2025. The low is $10 issued by JP Morgan on August 12, 2024. The 3 most-recent analyst ratings were released by Needham, Needham, and HC Wainwright & Co. on May 9, 2025, April 8, 2025, and April 8, 2025, respectively. With an average price target of $42.33 between Needham, Needham, and HC Wainwright & Co., there's an implied 65.66% upside for Pacira BioSciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Barclays
Truist Securities
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Pacira BioSciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | 17.39% | Needham | Serge Belanger72% | $32 → $30 | Maintains | Buy | Get Alert |
| 04/08/2025 | Buy Now | 25.22% | Needham | Serge Belanger72% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | 154.35% | HC Wainwright & Co. | Oren Livnat61% | $48 → $65 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | -6.08% | Barclays | Balaji Prasad56% | $17 → $24 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 25.22% | Needham | Serge Belanger72% | $30 → $32 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 173.92% | HC Wainwright & Co. | Oren Livnat61% | $57 → $70 | Maintains | Buy | Get Alert |
| 01/30/2025 | Buy Now | -2.17% | Truist Securities | Les Sulewski21% | $8 → $25 | Upgrade | Sell → Hold | Get Alert |
| 01/14/2025 | Buy Now | -29.56% | RBC Capital | Gregory Renza41% | $18 → $18 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/13/2025 | Buy Now | 17.39% | Needham | Serge Belanger72% | $22 → $30 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 17.39% | Needham | Serge Belanger72% | $22 → $30 | Maintains | Buy | Get Alert |
| 12/04/2024 | Buy Now | 52.61% | HC Wainwright & Co. | Oren Livnat61% | $39 → $39 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | -33.48% | Barclays | Balaji Prasad56% | $25 → $17 | Maintains | Equal-Weight | Get Alert |
| 11/08/2024 | Buy Now | -13.91% | Needham | Serge Belanger72% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | -37.39% | RBC Capital | Gregory Renza41% | $15 → $16 | Maintains | Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | -41.3% | RBC Capital | Gregory Renza41% | $14 → $15 | Maintains | Sector Perform | Get Alert |
| 09/24/2024 | Buy Now | -29.56% | Jefferies | Glen Santangelo50% | $15 → $18 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | -68.69% | Truist Securities | Les Sulewski21% | $30 → $8 | Downgrade | Buy → Sell | Get Alert |
| 08/12/2024 | Buy Now | -45.22% | RBC Capital | Gregory Renza41% | $37 → $14 | Downgrade | Outperform → Sector Perform | Get Alert |
| 08/12/2024 | Buy Now | 52.61% | HC Wainwright & Co. | Oren Livnat61% | $57 → $39 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | -13.91% | Needham | Serge Belanger72% | $43 → $22 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | -60.87% | JP Morgan | Hardik Parikh10% | $45 → $10 | Downgrade | Overweight → Underweight | Get Alert |
| 08/01/2024 | Buy Now | 17.39% | Jefferies | Glen Santangelo50% | $36 → $30 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | 44.79% | Raymond James | Gary Nachman58% | $41 → $37 | Maintains | Outperform | Get Alert |
| 07/31/2024 | Buy Now | 44.79% | RBC Capital | Gregory Renza41% | $42 → $37 | Maintains | Outperform | Get Alert |
| 07/31/2024 | Buy Now | 68.26% | Needham | Serge Belanger72% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2024 | Buy Now | 17.39% | Truist Securities | Les Sulewski21% | $45 → $30 | Maintains | Buy | Get Alert |
| 07/03/2024 | Buy Now | 64.35% | Piper Sandler | David Amsellem78% | $42 → $42 | Maintains | Overweight | Get Alert |
| 07/03/2024 | Buy Now | -2.17% | Barclays | Balaji Prasad56% | $38 → $25 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/02/2024 | Buy Now | 76.09% | Truist Securities | Les Sulewski21% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 07/02/2024 | Buy Now | 68.26% | Needham | Serge Belanger72% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 07/02/2024 | Buy Now | 123.05% | HC Wainwright & Co. | Oren Livnat61% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2024 | Buy Now | 40.87% | Jefferies | Glen Santangelo50% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 123.05% | HC Wainwright & Co. | Oren Livnat61% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 48.7% | Barclays | Balaji Prasad56% | $40 → $38 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | 68.26% | Needham | Serge Belanger72% | $45 → $43 | Maintains | Buy | Get Alert |
| 04/09/2024 | Buy Now | 76.09% | Needham | Serge Belanger72% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 76.09% | JP Morgan | Hardik Parikh10% | → $45 | Assumes | → Overweight | Get Alert |
| 03/04/2024 | Buy Now | 40.87% | Jefferies | Glen Santangelo50% | $38 → $36 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 56.53% | Barclays | Balaji Prasad56% | $50 → $40 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | 123.05% | HC Wainwright & Co. | Oren Livnat61% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 76.09% | Needham | Serge Belanger72% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 76.09% | RBC Capital | Gregory Renza41% | $53 → $45 | Maintains | Outperform | Get Alert |
| 02/08/2024 | Buy Now | 123.05% | Wedbush | Andreas Argyrides70% | $57 → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 12/20/2023 | Buy Now | 64.35% | Raymond James | Gary Nachman58% | → $42 | Initiates | → Outperform | Get Alert |
| 11/06/2023 | Buy Now | 123.05% | HC Wainwright & Co. | Oren Livnat61% | $63 → $57 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 64.35% | Piper Sandler | David Amsellem78% | $50 → $42 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | 126.96% | RBC Capital | Gregory Renza41% | $67 → $58 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 76.09% | Needham | Serge Belanger72% | $52 → $45 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | 76.09% | Truist Securities | Les Sulewski21% | $50 → $45 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 123.05% | Barclays | Balaji Prasad56% | $60 → $57 | Maintains | Overweight | Get Alert |
| 10/13/2023 | Buy Now | 95.66% | Truist Securities | Gregory Francfort70% | $55 → $50 | Maintains | Buy | Get Alert |
| 10/03/2023 | Buy Now | 166.09% | RBC Capital | Gregory Renza41% | → $68 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | Buy Now | 95.66% | Piper Sandler | David Amsellem78% | $60 → $50 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | 115.22% | Truist Securities | Les Sulewski21% | $60 → $55 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 166.09% | RBC Capital | Gregory Renza41% | $70 → $68 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | 95.66% | TD Cowen | Boris Peaker40% | → $50 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/03/2023 | Buy Now | 146.53% | HC Wainwright & Co. | Oren Livnat61% | $68 → $63 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 103.48% | Needham | Serge Belanger72% | $60 → $52 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | 166.09% | HC Wainwright & Co. | Oren Livnat61% | $71 → $68 | Maintains | Buy | Get Alert |
| 05/15/2023 | Buy Now | 134.79% | Piper Sandler | David Amsellem78% | → $60 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | 181.75% | RBC Capital | Gregory Renza41% | $75 → $72 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | 177.83% | HC Wainwright & Co. | Oren Livnat61% | → $71 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 142.61% | Piper Sandler | David Amsellem78% | → $62 | Maintains | Overweight | Get Alert |
| 04/20/2023 | Buy Now | 134.79% | Needham | Serge Belanger72% | → $60 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 197.4% | RBC Capital | Gregory Renza41% | $80 → $76 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 177.83% | HC Wainwright & Co. | Oren Livnat61% | $69 → $71 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 134.79% | Needham | Serge Belanger72% | $63 → $60 | Maintains | Buy | Get Alert |
| 02/10/2023 | Buy Now | 170.01% | HC Wainwright & Co. | Oren Livnat61% | $76 → $69 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | 134.79% | Wedbush | Andreas Argyrides70% | → $60 | Assumes | → Outperform | Get Alert |
| 01/06/2023 | Buy Now | 103.48% | BMO Capital | Gary Nachman58% | $60 → $52 | Maintains | Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 146.53% | Needham | Serge Belanger72% | $66 → $63 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | 134.79% | BMO Capital | Gary Nachman58% | $66 → $60 | Maintains | Market Perform | Get Alert |
| 11/04/2022 | Buy Now | 197.4% | HC Wainwright & Co. | Oren Livnat61% | $83 → $76 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 189.57% | Needham | Serge Belanger72% | $76 → $74 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 158.27% | Jefferies | Glen Santangelo50% | → $66 | Assumes | → Buy | Get Alert |
| 08/04/2022 | Buy Now | 197.4% | Piper Sandler | David Amsellem78% | $80 → $76 | Maintains | Overweight | Get Alert |
| 07/21/2022 | Buy Now | 213.05% | Piper Sandler | David Amsellem78% | $84 → $80 | Maintains | Overweight | Get Alert |
| 06/15/2022 | Buy Now | 197.4% | Needham | Serge Belanger72% | $84 → $76 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Pacira BioSciences (PCRX) stock?
The latest price target for Pacira BioSciences (NASDAQ:PCRX) was reported by Needham on May 9, 2025. The analyst firm set a price target for $30.00 expecting PCRX to rise to within 12 months (a possible 17.39% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacira BioSciences (PCRX)?
The latest analyst rating for Pacira BioSciences (NASDAQ:PCRX) was provided by Needham, and Pacira BioSciences maintained their buy rating.
When was the last upgrade for Pacira BioSciences (PCRX)?
The last upgrade for Pacira BioSciences Inc happened on January 30, 2025 when Truist Securities raised their price target to $25. Truist Securities previously had a sell for Pacira BioSciences Inc.
When was the last downgrade for Pacira BioSciences (PCRX)?
The last downgrade for Pacira BioSciences Inc happened on August 13, 2024 when Truist Securities changed their price target from $30 to $8 for Pacira BioSciences Inc.
When is the next analyst rating going to be posted or updated for Pacira BioSciences (PCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating Pacira BioSciences (PCRX) correct?
While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a maintained with a price target of $32.00 to $30.00. The current price Pacira BioSciences (PCRX) is trading at is $25.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
